Levobupivacaina Bioindustria L.I.M (Levobupivacaine Hydrochloride)

Levobupivacaine works by reversibly binding to voltage‑gated sodium channels on neuronal membranes. This stabilizes the channels in an inactive state, preventing the influx of sodium ions required for depolarisation, thereby blocking nerve impulse conduction and producing a localized loss of sensation.

The appropriate dose of Levobupivacaina Bioindustria L.I.M is determined by the prescribing clinician based on the specific procedure, patient characteristics, and desired depth of anesthesia. Dosage is individualized and should follow current clinical guidelines and the product’s prescribing information.

Safety data for levobupivacaine in pregnancy and lactation are limited. It may be used in obstetric anesthesia when the benefits outweigh potential risks, but clinicians should exercise caution, monitor fetal status, and consider alternative agents if uncertainty exists. Breastfeeding considerations follow standard local‑anesthetic guidance.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine, offering a similar duration of action with a lower risk of cardiotoxicity and central‑nervous‑system toxicity. Compared with racemic bupivacaine, it provides comparable analgesia while improving safety margins, especially in high‑dose or continuous infusion settings.

Levobupivacaina should be stored below 25 °C, protected from light, moisture and extreme temperatures. Keep the solution in its original, sealed container. Do not freeze. Inspect the vial for particulate matter or discoloration before use and follow aseptic techniques during preparation.

The product is administered by a qualified healthcare professional via the epidural route. After aseptic skin preparation, the sterile solution is injected into the epidural space using a catheter or needle, with careful aspiration to avoid intravascular placement and monitoring of patient response.

Serious risks include central‑nervous‑system toxicity (seizures, loss of consciousness), cardiac arrhythmias or cardiac arrest, and severe allergic reactions such as anaphylaxis. Early recognition of symptoms and immediate supportive measures are essential to mitigate these potentially life‑threatening events.

Levobupivacaina is contraindicated in patients with known hypersensitivity to levobupivacaine or other amide‑type local anesthetics, in those with severe cardiac conduction disorders, and in individuals where epidural injection is technically unsafe. Caution is also advised for patients with significant hepatic impairment.